<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04060758</url>
  </required_header>
  <id_info>
    <org_study_id>LATA CS102</org_study_id>
    <nct_id>NCT04060758</nct_id>
  </id_info>
  <brief_title>Open Label, Sequential-dose Study of PA5108 Latanoprost FA SR Ocular Implant for Mild-moderate Glaucoma</brief_title>
  <official_title>An Open Label, Comparative, Sequential-dose, Multi-centre Study Involving Intracameral Administration of a PA5108 Latanoprost FA SR Ocular Implant Into the Eye of Patients With Mild-moderate Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PolyActiva Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PolyActiva Pty Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-centre, open label, interventional, comparative, phase I study to identify a&#xD;
      safe and efficacious dose (within the range of 14.7mcg to 35.5 mcg) of PA5108 (PolyActiva&#xD;
      product code) Latanoprost free acid (FA) sustained release (SR) Ocular Implant in adults who&#xD;
      have Primary Open Angle Glaucoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-centre, open label, interventional, comparative, phase Ib dose ranging study&#xD;
      to identify a safe and efficacious dose (within the range of 14.7 to 35.5 microgram) of&#xD;
      PA5108 Latanoprost FA SR Ocular Implant in adults who have Primary Open Angle Glaucoma&#xD;
      (POAG).&#xD;
&#xD;
      The proposed study is a single ascending dose design to determine the minimum effective dose&#xD;
      that provides the target of &gt;20% IOP lowering effect at 12 weeks with minimal adverse events.&#xD;
&#xD;
      Up to three cohorts will be assessed from the following implant strengths:&#xD;
&#xD;
        -  35.5 microgram&#xD;
&#xD;
        -  26.6 microgram&#xD;
&#xD;
        -  14.7 microgram&#xD;
&#xD;
      A first cohort of participants will be recruited and dosed with the 14.7 mcg PA5108&#xD;
      Latanoprost FA SR Ocular Implant. A second cohort of participants will be recruited after SMC&#xD;
      review of 6-week data of the first cohort and dosed with the 26.6 mcg PA5108 Latanoprost FA&#xD;
      SR Ocular Implant. A third cohort of participants will be recruited after SMC review of&#xD;
      6-week data of the second cohort and dosed with 35.5 mcg PA5108 Latanoprost FA SR Ocular&#xD;
      Implant.&#xD;
&#xD;
      Prior to study registration, participants will have been medicated with intraocular pressure&#xD;
      (IOP) lowering drop therapy, including a prostaglandin analogue, to manage their POAG. The&#xD;
      IOP lowering drops will be stopped in the intent to treat eye within 29 to 43 days prior to&#xD;
      the date of implant administration. Participants will be required to have an unmedicated&#xD;
      (post wash-out) 8:00am IOP ≥ 24 mmHg and ≤ 36mmHg in the intent to treat eye at either of two&#xD;
      screening visits 2-weeks apart. Additionally, the IOP at 12:00 noon and 4:00 pm must be ≥&#xD;
      20mmHg and ≤ 36mmHg on the same screening visit where the 8:00am IOP was ≥ 24 mmHg and ≤&#xD;
      36mmHg.&#xD;
&#xD;
      The PA5108 Latanoprost FA SR Ocular Implant will be administered to one eye (unilateral) of&#xD;
      each participant.&#xD;
&#xD;
      IOP will be monitored and if after implant administration is found to rise ≥30% over baseline&#xD;
      in the study eye, IOP lowering eye drops will be restarted.&#xD;
&#xD;
      The study will recruit up to 10 participants per cohort/dose level. After screening, eligible&#xD;
      participants will be administered a single PA5108 Latanoprost FA SR Ocular Implant by clear&#xD;
      corneal injection to the anterior chamber of the eye, by means of a custom-built injector&#xD;
      fitted with a 27G pre-loaded needle.&#xD;
&#xD;
      The study will end at the later of Visit 7 (32-weeks) for the last participant in the study,&#xD;
      or when the last of the study implants are no longer visible in the study eye and the IOP in&#xD;
      the same eye has returned to a normal clinical care range, or 12-weeks has passed since the&#xD;
      implant was no longer visible regardless of IOP.&#xD;
&#xD;
      Participants will attend the study site for follow up on Day 1 post implant administration,&#xD;
      and then Week 6, 12, (optionally 15), 18, (optionally 21), 26, 32 and if required subsequent&#xD;
      6-week intervals until the implant has completely biodegraded and the IOP of the same eye has&#xD;
      returned to normal clinical care range or 12-weeks has passed since the implant was no longer&#xD;
      visible. Implant biodegradation will be confirmed by biomicroscopy and gonioscopy examination&#xD;
      at Week 12, optionally 15, 18, optionally 21, 26 &amp; 32, and if necessary, every 6-weeks&#xD;
      thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 11, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effective dose</measure>
    <time_frame>Intraocular Pressure (IOP) change measured at; baseline, week 12 and week 26.</time_frame>
    <description>Determine the minimum effective dose (as daily release rate of LtpFA) that achieves an IOP lowering effect &gt;20% with minimal adverse events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability-incidence of treatment emergent Adverse Events</measure>
    <time_frame>Incidence of Treatment-Emergent Adverse Events throughout the study (up to 1 year).</time_frame>
    <description>Assess the safety and tolerability of PA5108 Latanoprost FA SR Ocular Implant in adults with Open Angle Glaucoma (Primary). Incidence of Treatment-Emergent Adverse Events from visit 1 until end of study. Safety laboratory evaluations (biochemistry, haematology, urinalysis). Physical examinations and vital signs. Changes in ocular examinations from baseline to end of study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ease of Use</measure>
    <time_frame>At visit 2-Day 0, after use of device to insert the implant into the eye.</time_frame>
    <description>Assess the ease of use of the bespoke administration device- Administering ophthalmologist's assessment of ease of use of the bespoke administration device, verbal communication.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Open Angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>14.7 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PA5108 Latanoprost FA SR Ocular Implant which releases 14.7 mcg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>26.6 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PA5108 Latanoprost FA SR Ocular Implant which releases 26.6 mcg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>35.5 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PA5108 Latanoprost FA SR Ocular Implant which releases 35.5 mcg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PA5108 Latanoprost FA SR Ocular Implant</intervention_name>
    <description>Ocular Implant</description>
    <arm_group_label>14.7 mcg</arm_group_label>
    <arm_group_label>26.6 mcg</arm_group_label>
    <arm_group_label>35.5 mcg</arm_group_label>
    <other_name>PA5108</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Participants who:&#xD;
&#xD;
          -  Diagnosis of primary open angle glaucoma.&#xD;
&#xD;
          -  Unmedicated 8:00am IOP ≥ 24 mmHg and ≤ 36mmHg in the intent to treat eye.&#xD;
             Additionally, the IOP at 12:00 and 16:00 hrs must be ≥ 20mmHg and ≤ 36mmHg.&#xD;
&#xD;
          -  Corrected visual acuity in each eye greater than or equal to +0.3logMAR.&#xD;
&#xD;
          -  Minimum central endothelial cell density of greater than or equal to 1600 cells per&#xD;
             mm2&#xD;
&#xD;
          -  Currently managing their POAG with IOP lowering drop therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Participants who:&#xD;
&#xD;
          -  Have pseudoexfoliation or pigment dispersion component, history of angle closure, or&#xD;
             narrow angles.&#xD;
&#xD;
          -  Have a history of or current ocular inflammation.&#xD;
&#xD;
          -  Have aphakic eyes or only one eye.&#xD;
&#xD;
          -  Recent surgery in the study eye surgery (including laser).&#xD;
&#xD;
          -  Clinically significant ocular disease in either eye (e.g., corneal oedema, uveitis,&#xD;
             severe keratoconjunctivitis sicca or infection) which might interfere with the study.&#xD;
&#xD;
          -  Known sensitivity to any component of the product (e.g. latanoprost or polytriazole&#xD;
             sensitivity), or to topical therapy used during course of study (e.g. povidone iodine,&#xD;
             or anaesthetics).&#xD;
&#xD;
          -  Ocular medication in either eye of any kind within 30 days of screening.&#xD;
&#xD;
          -  Central corneal thickness in either eye that is less than 470 µm or greater than 630&#xD;
             µm at screening (or a difference between the eyes &gt;70 µm).&#xD;
&#xD;
          -  Any abnormality in either eye preventing reliable applanation tonometry, including&#xD;
             aphakic eyes or significant corneal guttatae.&#xD;
&#xD;
          -  Any other clinically significant disease (as determined by physician) which might&#xD;
             interfere with the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Coote</last_name>
    <role>Principal Investigator</role>
    <affiliation>Melbourne Eye Specialists</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Russell Tait</last_name>
    <phone>+61396570700</phone>
    <email>russell.tait@polyactiva.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>PersonalEYES</name>
      <address>
        <city>Castle Hill</city>
        <state>New South Wales</state>
        <zip>2150</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Macquarie Hospital</name>
      <address>
        <city>Macquarie Park</city>
        <state>New South Wales</state>
        <zip>2109</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eye Associates</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Goodwood Eye Centre</name>
      <address>
        <city>Millswood</city>
        <state>South Australia</state>
        <zip>5034</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bendigo Eye Clinic</name>
      <address>
        <city>Bendigo</city>
        <state>Victoria</state>
        <zip>3550</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre for Eye Research Australia</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Essendon Eye Clinic</name>
      <address>
        <city>Essendon</city>
        <state>Victoria</state>
        <zip>3040</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melbourne Eye Specialists</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Coote</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eyes First</name>
      <address>
        <city>Springvale</city>
        <state>Victoria</state>
        <zip>3171</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>August 5, 2019</study_first_submitted>
  <study_first_submitted_qc>August 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2019</study_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Latanoprost</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

